Baker McKenzie Baker McKenzie
How Can We Help?
  • Home
  • Expertise
  • 医疗与生命科学
Language:
中文(简体)

医疗与生命科学

blue and violet wire-shaped patterns against a blue background
Insight | Topic

Healthcare & Life Sciences Hub

Stay apprised on key market trends, risks, opportunities and legal issues through our dedicated resources hub.
Read More

Healthcare and life sciences companies face immense opportunity and disruption. The increasing innovation in new product breakthroughs; interplay between drugs, devices and tech; cost pressures; and demand for patient centricity have created a melting pot for agility and change.

Businesses turn to Baker McKenzie to enter new markets, maximize operational efficiencies, build a long-term pipeline of innovative products and demonstrate efficacy. We provide commercial legal advice to help anticipate and manage new risk and avoid disconnect between global strategy and the law enabling your company to provide better care to patients across the globe.

Visit InsightPlus for our latest legal updates covering Healthcare & Life Sciences developments across the globe

Insight | 宣传册
Looking Ahead: Business Impacts of the Trump Administration
As Donald Trump takes office as the 47th US president, Baker McKenzie practitioners outline the business implications that we expect to see across a range of areas.
Insight | 书籍
Quick Guide to Market Access in the Latin America Healthcare and Life Sciences Sector
This guide provides initial insights into accessing public health systems and the regulations governing available drugs in Latin America. 
Insight | 书籍
Ukrainian Laws in Wartime
Our guide provides an overview of the key features of wartime legislation.
Insight | 书籍
Doing Business in the United Arab Emirates 2024
Comprehensive guide to understanding the current investment and legal landscape in the UAE.
Insight | 客户/法律动态
UK General Election Manifesto and Policy Tracker
A summary of the policies outlined in the Conservative and Labour manifestos and an indication of what the potential impact on businesses and individuals may be.
Insight | 宣传册
Unlocking and Accelerating Growth: Healthcare and Life Sciences in Asia Pacific
Healthcare and life sciences breakthroughs offer opportunities to meet patient needs and create value, but rising costs and market uncertainty also apply significant pressure to operations.
Insight | 客户/法律动态
WHO Releases AI Ethics and Governance Guidance for Large Multimodal Models
The WHO guidance summarizes the broad applications of LMMs in the healthcare industry, including recommendations for governments, and for public health and medical purposes.
Insight | 宣传册
The Year Ahead: Global Disputes Forecast 2024 Report
Our seventh annual report provides detailed analysis of disputes trends to prepare your organization for 2024.
Insight | 客户/法律动态
Supporting clients to seize Korea’s substantial opportunities
Our lawyers discuss the abundant opportunities that Korea presents and how the JV supports clients with their Korea inbound and outbound investments and business expansion. 
Insight | 书籍
Guide to IPOs for Biotech and Pharma Companies
Biotech and pharma companies undertaking capital raisings can approach the world’s capital markets in various ways.
Insight | Podcast
Talking M&A
From navigating the complexities of carve-outs or tech transactions to cross-border trends, gain expert insights and uncover key topics in a complex transactional landscape.
View All Insight
News | Insight
Baker McKenzie Annual Disputes Survey: Technology-Related Issues Top 2025 Disputes Risk
The report looks at the disputes landscape for the year ahead across various sectors and offers actionable insights to help organizations prepare for the future.
News | Press Coverage
Deal Digest – October / November 2024
M&A, private equity and other complex transactions from across the globe
News | 交易公告
Baker McKenzie Advises ATB Therapeutics on EUR 54 million Series A Financing
With this financing, ATB Therapeutics will advance the development of oncology and immunology drug candidates based on its patented ATBioFarm platform. 
News
Deal Digest: Q3 2024
M&A, private equity and other complex transactions from across the globe
News | 交易公告
Baker McKenzie Client Lundbeck to Acquire Longboard in USD 2.6 Billion Transaction
The proposed acquisition represents a significant step forward in Lundbeck’s Focused Innovator strategy.
News | 本所新闻
Experienced AI and Healthcare Technology Lawyer Keo McKenzie Rejoins Baker McKenzie as a Partner in Washington, DC
With over a decade of experience in a range of regulatory and transactional issues, Keo focuses on those involving AI and digital health technologies.
News | 本所新闻
Baker McKenzie Continues Growth of Global M&A Practice with High-Calibre Team Hire in Singapore
In Singapore, we welcome new additions to the team, led by principals Shirin Tang and Ang Lip Kian, joining from Morrison Foerster.
News | 奖项
Baker McKenzie Secures Top Rankings in the 2024 Edition of "Ukrainian Law Firms: A Handbook for Foreign Clients"
The rankings highlight the Firm's leadership in complex transactional, corporate and regulatory matters across various industries.
News | 交易公告
Baker McKenzie Advises Baxter in USD 3.8 Billion Divestiture of Vantive Kidney Care Segment to Carlyle
The deal represents a key milestone in Baxter’s ongoing business transformation, enabling heightened strategic clarity, operational efficiency and innovation.
News | Press Coverage
Singapore taps Vietnam for M&A/ investment opportunities; healthcare, real estate and construction sectors are key focus
M&A partner Seck Yee Chung shares his views about the future outlook of Singapore M&A deals in Vietnam.
News | Press Coverage
Alan Zoccolillo speaks to Mergermarket / Ion Analytics about deal activity in the North America healthcare sector
Alan Zoccolillo, discussed with Mergermarket/Ion Analytics the current trends driving the market and the near-term outlook for M&A activity in the sector.
浏览全部新闻

Ranked in the Top 4 Law Firms in the World for Life Sciences, Chambers Global

Americas

  • Ranked in Healthcare: Pharmaceutical/Medical Products Regulatory, Chambers USA 2024 (District of Columbia)
  • Band 1 for Life Sciences, Chambers Latin America 2024 (Mexico)
  • Band 2 for Life Sciences and Healthcare, Chambers Latin America 2024 (Peru)
  • Tier 1 for Life Sciences and Healthcare, Legal 500 Latin America 2024 (Argentina)
  • Tier 1 for Life Sciences, Legal 500 Latin America 2024 (Mexico)
  • Tier 2 for Life Sciences, Legal 500 Latin America 2024 (Colombia)
  • Impact Deal of the Year - Poseida Therapeutics/Takeda, LMG Life Sciences Americas 2022 (US)
  • Impact Deal of the Year - Pfizer/Trillium Therapeutics, LMG Life Sciences Americas 2022 (Canada)
  • FDA Regulatory Firm to Watch, LMG Life Sciences Awards 2020 (US)
  • Licensing and Collaborations Recommended Firm, LMG Life Sciences 2021 and 2020 (US)

Europe, Middle East and Africa

  • Band 1 for Life Sciences, Chambers Europe 2024 (Hungary)
  • Band 2 for Life Sciences, Chambers Europe 2024 (Germany and Spain)
  • Listed for Healthcare & Life Sciences (Industry Focus and Regulatory), Legal 500 EMEA 2024 (Germany)
  • Tier 2 for Healthcare & Life Sciences (Industry Focus), Legal 500 EMEA 2024 (France, Italy, Spain)
  • Tier 2 for Healthcare & Life Sciences (Industry Focus), Legal 500 UK 2024 (London)
  • Law Firm of the Year for Health and Research, Top Legal Industry Awards (Italy)
  • Regulatory Firm of the Year, LMG Life Sciences EMEA 2022 (Türkiye) - Esin Attorney Partnership (a Member Firm of Baker McKenzie International)
  • Türkiye Firm of the Year, LMG Life Sciences EMEA 2022 (Türkiye) - Esin Attorney Partnership (a Member Firm of Baker McKenzie International)
  • Impact Deal - Vifor Pharma/Sanifit, LMG Life Sciences EMEA 2022 (Türkiye) - Esin Attorney Partnership (a Member Firm of Baker McKenzie International)

Asia Pacific

  • Band 1 for Life Sciences (Asia Pacific Region), Chambers Global 2014 to 2024 Chambers Asia Pacific 2014 to 2024
  • Band 2 for Life Sciences, Chambers Asia Pacific 2024 (Australia)
  • Band 2 for Life Sciences (International Firms), Chambers Greater China Region 2024 (China)
  • Tier 2 for Healthcare and Life Sciences (Foreign Firms), Legal 500 Asia Pacific 2023 (China)

How We Can Help

Explore Healthcare & Life Sciences

Healthcare and Life Sciences video still

About Us

Learn about our Global Healthcare & Life Sciences Industry Group in five minutes.


Healthtech and Biotech M&A

The healthcare tech and biotech industries shifted fundamentally during the pandemic. Enthusiasm for dealmaking continues to be a growth area.

>> 16-minute listen

Flares of different colored light against a black background

Guide to IPOs for Biotech and Pharma Companies

Biotech and pharma companies undertaking capital raisings can approach the world’s capital markets in various ways.


Global Healthcare & Life Sciences Webinar Series

Aims to share legal industry insights and provide practical guidance in the context of today's evolving world.


Key Contacts